Reportlinker Adds The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities

Jan 19, 2010, 07:53 ET from Reportlinker

NEW YORK, Jan. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities

http://www.reportlinker.com/p0172209/The-Cancer-Market-Outlook-To-2014-Competitive-landscape-market-size-pipeline-analysis-and-growth-opportunities.html

In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built.

Key features of this report

  • Epidemiological analysis and forecast prevalence of the major cancer indications over the period 2008-14 including lung, breast, colorectal, ovarian cancer markets.
  • Forecasts and analysis of the major products in the cancer market over the period 2008-14 spread across the major indications and classes of treatments.
  • Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.
  • Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.

Scope of this report

  • Develop insight into patient potential with the report's coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and 10 largest companies active in the cancer segment today
  • Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in cancer marketplace
  • Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players
  • Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities

Key Market Issues

  • FDA approves Cervarix for cervical cancer

In October 2009, FDA approved GSK's Cervarix for the prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged 10–25 years. Cervarix's inclusion in children's vaccine program is a major step towards securing reimbursement. Cervarix, expected to launch by the end of 2009, faces direct competition from Merck's Gardasil and will help to reduce the incidence of cervical cancer in future.

  • Merck's Gardasil adds US indication of genital warts for boys and men

On 16th October 2009, Gardasil's US label was extended to include its use in both men and boys aged 9–26 years of age. The pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types 6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free Gardasil to 19–26 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.

Key findings from this report

  • In 2008, antineoplastic mAbs delivered huge sales of $13.6bn with a market share of 28.6% of total sales. The key antineoplastic mAbs which contributed to the higher market share of this class in 2008 were MabThera (11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%). Forecast sales of the total antineoplastics market are estimated at $65.2bn in 2014.
  • Roche is the global market leader in cancer, holding the highest market share of 29.2% ($14.0bn sales) in 2008 based on sales from (MabThera, Avastin, Herceptin, Tarceva and Xeloda). Roche's strength in the cancer market has been bolstered by its acquisition of Genentech and purchase of majority stakes in Chugai, which has provided additional breadth to its portfolio.
  • Eli Lilly's acquisition of ImClone will increase the former's flow of high-quality, innovative new therapies. The transaction will immediately enable Eli Lilly to offer physicians and their patients a complementary portfolio of leading oncolytic agents and targeted therapies including Gemzar, Alimta and Erbitux.

Key questions answered

  • What will be the major growth indications in the cancer segment over the period 2008–14?
  • Which companies were the winners and losers in the cancer segment in 2008?
  • How have recent major launches from companies such as Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly performed?
  • Which companies will become the key players in the cancer segment over the period 2008–14?
  • Which products will be impacted by generic competitors over the period 2008–14?

Table of Contents

The Cancer Market Outlook to 2014

Executive Summary 12

Epidemiology of Cancer 12

Global Market Analysis 13

Pipeline Analysis 14

Competitive Landscape 15

Chapter 1 Scope and methodology 18

Scope 18

Methodology 19

Chapter 2 Overview and epidemiology of cancer indications 22

Summary 22

Introduction 23

Overview 23

Cancer risk factors 23

Lung cancer 24

Overview 24

Diagnosis, treatment and management 25

Epidemiology 27

NSCLC 27

SCLC 28

Forecast epidemiology 29

NSCLC 29

SCLC 30

Colorectal cancer 31

Overview 31

Diagnosis, treatment and management 31

Epidemiology 32

Forecast epidemiology 33

Breast cancer 34

Overview 34

Diagnosis, treatment and management 35

Epidemiology 36

Forecast epidemiology 37

Ovarian cancer 38

Overview 38

Diagnosis, treatment and management 39

Epidemiology 40

Forecast epidemiology 41

Uterine and cervical cancer 42

Overview 42

Diagnosis, treatment and management 43

Epidemiology 44

Forecast epidemiology 44

Leukemia 45

Overview 45

Diagnosis, treatment and management 47

Epidemiology 48

Forecast epidemiology 48

Prostate cancer 49

Overview 49

Diagnosis, treatment and management 50

Epidemiology 51

Forecast epidemiology 51

Pancreatic cancer 53

Overview 53

Diagnosis, treatment and management 53

Epidemiology 54

Forecast epidemiology 54

Lymphomas 56

Overview 56

Diagnosis, treatment and management 56

Epidemiology 57

Forecast epidemiology 58

Head and neck cancer 60

Overview 60

Diagnosis, treatment and management 61

Epidemiology 62

Forecast epidemiology 62

Chapter 3 Global market analysis 66

Summary 66

Introduction 67

Market analysis by country 67

Market analysis by drug class 69

Leading brand dynamics 70

MabThera (rituximab) –Roche/Genentech 71

Avastin (bevacizumab) – Roche/Genentech 73

Herceptin (trastuzumab) – Roche/Genentech/Chugai 74

Glivec/Gleevec (imatinib) – Novartis 75

Taxotere (docetaxel) – Sanofi-Aventis 76

Leading brands by type of cancer 77

Key recent events in the cancer market 80

FDA approves Cervarix for cervical cancer 80

Merck's Gardasil adds US indication of genital warts for boys and men 80

Roche's Avastin is filed for first-line breast cancer in Japan 80

Eisai to file first in-house breast cancer drug in major markets 81

Novartis's Tasigna bolsters its CML franchise 81

Antineoplastics 82

Competitive dynamics of antineoplastics 82

Leading brands of antineoplastics 84

Antineoplastic mAb market analysis 86

Market dynamics 86

Key brands analysis 86

Antineoplastic protein kinase inhibitors 88

Market dynamics 88

Key brands analysis 89

Vinca alkaloid market analysis 89

Market dynamics 89

Key brands analysis 90

Anti-metabolites 90

Market dynamics 90

Key brands analysis 90

Platinum compounds 92

Market dynamics 92

Key brands analysis 92

Antineoplastic sales forecast 93

Cytostatic hormonal therapies 94

Competitive dynamics of cytostatic hormonal therapies 94

Leading brands of cytostatic hormonal therapies 95

Cytostatic gonad hormone analog market analysis 97

Market dynamics 97

Key brands analysis 97

Aromatase inhibitors 98

Market dynamics 98

Key brands analysis 99

Anti-androgens 101

Market dynamics 101

Key brand analysis 102

Cytostatic hormonal therapy sales forecast 103

Global cancer market sales forecast 104

Chapter 4 Pipeline analysis 106

Summary 106

Introduction 107

Key trends in R&D 107

Targeted therapies are changing the treatment regimen of cancer 107

Biomarkers are personalizing oncology treatment 108

Cancer vaccines enhance the body's immune response 109

Pricing is becoming a major issue for cancer patients 109

Combination treatments are becoming the treatment of choice 110

Leading drugs in development 111

Phase III and pending approval compounds 112

Enzastaurin – Eli Lilly 112

BiovaxID – Biovest International and Accentia Biopharmaceuticals 115

Recentin (cediranib) – AstraZeneca 117

Zactima (vandetanib) – AstraZeneca 120

Axitinib (AG-13736) – Pfizer 124

Provenge (sipuleucel-T) – Dendreon 126

Recently approved/marketed drugs 127

Arzerra (ofatumumab) – GSK/Genmab 127

Afinitor (everolimus) – Novartis 130

Iressa (gefitinib) – AstraZeneca 132

Tykerb/Tyverb (lapatinib) – GSK 133

Votrient (pazopanib) – GSK 137

Pipeline forecast of key compounds 139

Factors affecting forecasts 139

Chapter 5 Competitive landscape 142

Summary 142

Introduction 143

Sales performance of leading players 143

Roche 146

Sales focus by drug class 146

Regional sales distribution 147

Marketed product portfolio 148

Pipeline analysis 150

Strategic and growth analysis 151

Drivers of growth 151

Resistors of growth 152

Sanofi–Aventis 153

Sales focus by drug class 153

Regional sales distribution 154

Marketed product portfolio 155

Pipeline analysis 156

Strategic and growth analysis 157

Drivers of growth 157

Resistors of growth 158

AstraZeneca 159

Sales focus by drug class 159

Regional sales distribution 160

Marketed product portfolio 161

Pipeline analysis 162

Strategic and growth analysis 163

Drivers of growth 163

Resistors of growth 163

Novartis 164

Sales focus by drug class 164

Regional sales distribution 165

Marketed product portfolio 166

Pipeline analysis 167

Strategic and growth analysis 168

Drivers of growth 168

Resistors of growth 168

Eli Lilly 169

Sales focus by drug class 169

Regional sales distribution 169

Marketed product portfolio 170

Pipeline analysis 171

Strategic and growth analysis 171

Drivers of growth 171

Resistors of growth 172

Pfizer 173

Sales focus by drug class 173

Regional sales distribution 174

Marketed product portfolio 175

Pipeline analysis 176

Strategic and growth analysis 177

Drivers of growth 177

Resistors of growth 177

Takeda 177

Sales focus by drug class 178

Regional sales distribution 179

Marketed product portfolio 179

Pipeline analysis 180

Strategic and growth analysis 181

Drivers of growth 181

Resistors of growth 181

Bristol-Myers Squibb 182

Sales focus by drug class 182

Regional sales distribution 183

Marketed product portfolio 184

Pipeline analysis 185

Strategic and growth analysis 186

Drivers of growth 186

Resistors of growth 186

Chapter 6 Appendix 188

IMS Data 188

Antineoplastic and immunomodulating agents 188

L1: Antineoplastics 188

L2: Cytostatic hormone therapy 188

Forecast factors 188

Glossary 189

Abbreviations used in this report 189

Index 191

List of Figures

Figure 2.1: Types of breast cancers 35

Figure 2.2: Types of leukemia 46

Figure 2.3: Chemotherapy options for Hodgkin's disease 57

Figure 2.4: Head and neck cancers and their risk factors 60

Figure 3.5: Worldwide cancer market share by region, 2008 69

Figure 4.6: Current pharmacological treatment options for cancer 111

Figure 4.7: Key drugs in late-stage development or that have been recently launched 112

Figure 5.8: Contribution of the top 10 players to growth of the global cancer market, 2007–08 145

Figure 5.9: Roche's cancer sales by drug class, 2008 146

Figure 5.10: Sanofi–Aventis's cancer sales by drug class, 2008 153

Figure 5.11: AstraZeneca's cancer sales by drug class, 2008 159

Figure 5.12: Novartis's cancer sales by drug class, 2008 164

Figure 5.13: Pfizer's cancer sales by drug class, 2008 173

Figure 5.14: Takeda's cancer sales by drug class, 2008 178

Figure 5.15: BMS' cancer sales by drug class, 2008 182

List of Tables

Table 2.1: Estimated prevalence of NSCLC across seven major markets, 2008 27

Table 2.2: Estimated prevalence of SCLC across seven major markets, 2008 28

Table 2.3: Forecast epidemiology of NSCLC across seven major markets, 2008–14 29

Table 2.4: Forecast epidemiology of SCLC across seven major markets, 2008–14 30

Table 2.5: Estimated prevalence of colorectal cancer across seven major markets, 2008 33

Table 2.6: Forecast epidemiology of colorectal cancer across seven major markets, 2008–14 34

Table 2.7: Estimated prevalence of breast cancer across seven major markets, 2008 36

Table 2.8: Forecast epidemiology of breast cancer across seven major markets, 2008–14 38

Table 2.9: Estimated prevalence of ovarian cancer across seven major markets, 2008 40

Table 2.10: Forecast epidemiology of ovarian cancer across seven major markets, 2008–14 42

Table 2.11: Estimated prevalence of uterine and cervical cancer across seven major markets, 2008 44

Table 2.12: Forecast epidemiology of uterine and cervical cancer across seven major markets, 2008–14 45

Table 2.13: Estimated prevalence of leukemia across seven major markets, 2008 48

Table 2.14: Forecast epidemiology of leukemia across seven major markets, 2008–14 49

Table 2.15: Estimated prevalence of prostate cancer across seven major markets, 2008 51

Table 2.16: Forecast epidemiology of prostate cancer across seven major markets, 2008–14 52

Table 2.17: Estimated prevalence of pancreatic cancer across seven major markets, 2008 54

Table 2.18: Forecast epidemiology of pancreatic cancer across seven major markets, 2008–14 55

Table 2.19: Estimated prevalence of lymphomas across seven major markets, 2008 58

Table 2.20: Forecast epidemiology of lymphomas across seven major markets, 2008–14 59

Table 2.21: Estimated prevalence of head and neck cancer across seven major markets, 2008 62

Table 2.22: Forecast epidemiology of head and neck cancer across seven major markets, 2008–14 63

Table 3.23: Global cancer market by geography, 2008 68

Table 3.24: Breakdown of the global cancer market by drug class, 2008 69

Table 3.25: Leading brands in the global cancer market, 2008 71

Table 3.26: Leading brands in breast cancer, 2008 78

Table 3.27: Leading brands in colon cancer, 2008 78

Table 3.28: Leading brands in prostate cancer, 2008 79

Table 3.29: Leading brands in lung cancer, 2008 79

Table 3.30: Breakdown of the global antineoplastic market by drug class, 2008 83

Table 3.31: Leading brands in global antineoplastics market, 2008 85

Table 3.32: Chronology of new indication approvals for Eloxatine 93

Table 3.33: Antineoplastic sales forecast, 2008–14 93

Table 3.34: Breakdown of the global cytostatic hormonal therapies by drug class, 2008 95

Table 3.35: Leading brands in global cytostatic hormonal therapies market, 2008 96

Table 3.36: Cytostatic hormonal therapy sales forecast, 2008–14 103

Table 3.37: Global cancer market sales forecast, 2008–14 104

Table 4.38: An overview of enzastaurin 112

Table 4.39: An overview of BiovaxID 115

Table 4.40: An overview of Recentin 117

Table 4.41: The Horizon Study Program 118

Table 4.42: An overview of Zactima 120

Table 4.43: Overview of Zactima's Phase III development plan 122

Table 4.44: An overview of axitinib 124

Table 4.45: An overview of Provenge 126

Table 4.46: An overview of Arzerra 127

Table 4.47: An overview of Afinitor 130

Table 4.48: An overview of Iressa 132

Table 4.49: An overview of Tykerb/Tyverb 133

Table 4.50: An overview of Votrient 137

Table 4.51: Key pipeline and recently approved products sales forecast, 2008–14 139

Table 5.52: Leading players in the global cancer market, 2008–14 143

Table 5.53: Regional sales distribution of Roche, 2008 147

Table 5.54: Roche's cancer product portfolio, 2008 148

Table 5.55: Roche's cancer R&D product pipeline, October 2009 150

Table 5.56: Regional sales distribution of Sanofi-Aventis, 2008 154

Table 5.57: Sanofi–Aventis's cancer product portfolio, 2008 155

Table 5.58: Sanofi-Aventis's cancer R&D product pipeline, October 2009 156

Table 5.59: Regional sales distribution of AstraZeneca, 2008 160

Table 5.60: AstraZeneca's cancer product portfolio, 2008 161

Table 5.61: AstraZeneca's cancer R&D product pipeline, October 2009 162

Table 5.62: Regional sales distribution of Novartis, 2008 165

Table 5.63: Novartis' cancer product portfolio, 2008 166

Table 5.64: Novartis's cancer R&D product pipeline, October 2009 167

Table 5.65: Regional sales distribution of Eli Lilly, 2008 169

Table 5.66: Eli Lilly's cancer product portfolio, 2008 170

Table 5.67: Eli Lilly's cancer R&D product pipeline, October 2009 171

Table 5.68: Regional sales distribution of Pfizer, 2008 174

Table 5.69: Pfizer's cancer product portfolio, 2008 175

Table 5.70: Pfizer's cancer R&D product pipeline, October 2009 176

Table 5.71: Regional sales distribution of Takeda, 2008 179

Table 5.72: Takeda's cancer product portfolio, 2008 179

Table 5.73: Takeda's cancer R&D product pipeline, October 2009 180

Table 5.74: Regional sales distribution of BMS, 2008 183

Table 5.75: BMS' cancer product portfolio, 2008 184

Table 5.76: BMS' cancer R&D product pipeline, October 2009 185

To order this report:

Pharmaceutical Industry: The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com/p0172209